ICON Public Limited (NASDAQ:ICLR) Shares Purchased by Icon Wealth Advisors LLC

Icon Wealth Advisors LLC raised its stake in ICON Public Limited (NASDAQ:ICLR) by 861.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 13,215 shares of the medical research company’s stock after buying an additional 11,840 shares during the quarter. Icon Wealth Advisors LLC’s holdings in ICON Public were worth $3,797,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in ICON Public in the 2nd quarter valued at approximately $54,000. ORG Partners LLC purchased a new position in shares of ICON Public in the second quarter valued at $59,000. GAMMA Investing LLC raised its stake in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after buying an additional 87 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 42 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after acquiring an additional 226 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Stock Performance

Shares of NASDAQ:ICLR opened at $212.76 on Friday. The business has a 50-day moving average of $259.64 and a two-hundred day moving average of $298.45. The firm has a market capitalization of $17.55 billion, a PE ratio of 23.72, a P/E/G ratio of 1.45 and a beta of 1.25. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public Limited has a 12 month low of $183.38 and a 12 month high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $3.10 EPS. As a group, research analysts forecast that ICON Public Limited will post 13.42 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on ICLR shares. Truist Financial reduced their price target on shares of ICON Public from $363.00 to $295.00 and set a “buy” rating on the stock in a report on Monday, October 28th. StockNews.com downgraded shares of ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Robert W. Baird decreased their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $292.45.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.